Onconetix (NASDAQ:ONCO – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.
Valuation & Earnings
This table compares Onconetix and Voyager Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Onconetix | $810,000.00 | 4.01 | -$14.03 million | $248.12 | 0.00 |
| Voyager Therapeutics | $40.37 million | 3.74 | -$119.72 million | ($1.80) | -1.36 |
Profitability
This table compares Onconetix and Voyager Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
| Voyager Therapeutics | -312.63% | -57.92% | -45.00% |
Risk & Volatility
Onconetix has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Onconetix and Voyager Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 573.47%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Onconetix.
Institutional and Insider Ownership
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Voyager Therapeutics beats Onconetix on 10 of the 15 factors compared between the two stocks.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
